Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Change in Cash (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Change in Cash data on record, last reported at -$7.2 million in Q4 2025.

  • For Q4 2025, Change in Cash rose 10.9% year-over-year to -$7.2 million; the TTM value through Dec 2025 reached $515000.0, up 107.97%, while the annual FY2025 figure was $515000.0, 107.97% up from the prior year.
  • Change in Cash reached -$7.2 million in Q4 2025 per CLDX's latest filing, down from $13.0 million in the prior quarter.
  • Across five years, Change in Cash topped out at $80.3 million in Q1 2024 and bottomed at -$72.3 million in Q2 2024.
  • Average Change in Cash over 5 years is -$748250.0, with a median of -$6.7 million recorded in 2023.
  • Peak YoY movement for Change in Cash: plummeted 933.3% in 2023, then surged 304.94% in 2025.
  • A 5-year view of Change in Cash shows it stood at -$33.0 million in 2021, then skyrocketed by 132.83% to $10.8 million in 2022, then grew by 26.13% to $13.7 million in 2023, then plummeted by 158.79% to -$8.0 million in 2024, then increased by 10.9% to -$7.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were -$7.2 million in Q4 2025, $13.0 million in Q3 2025, and $5.9 million in Q2 2025.